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ABSTRACT
Cancer patients often experience weight loss caused by protein calorie 
malnutrition (PCM) during the course of the disease or treatment. PCM 
is expressed as severe if the patient has two or more of the following 
characteristics: obvious significant muscle wasting, loss of subcutaneous 
fat; nutritional intake of <50% of recommended intake for 2 weeks or more; 
bedridden or otherwise significantly reduced functional capacity; weight loss 
of >2% in 1 week, 5% in 1 month, or 7.5% in 3 months. Cancer anorexia-
cachexia syndrome (CACS) is a multifactorial condition of advanced PCM 
associated with underlying illness (in this case cancer) and is characterized 
by loss of muscle with or without loss of fat mass. Cachexia is defined as 
weight loss of more than 5% of body weight in 12 months or less in the 
presence of chronic disease. Hence with a chronic illness on board even a 
small amount of weight loss can open the door to cachexia. These nutritional 
challenges can lead to severe morbidity and mortality in cancer patients. 
In the clinic, the application of personalized medicine and the ability to 
withstand the toxic effects of anti-cancer therapies can be optimized when 
the patient is in nutritional homeostasis and is free of anorexia and cachexia. 
Routine assessment of nutritional status and appropriate intervention are 
essential components of the effort to alleviate effects of malnutrition on 
quality of life and survival of patients.
INTRODUCTION
Protein-Calorie Malnutrition (PCM) refers to a 
nutritional status in which reduced availability of nutrients 
leads to changes in body composition and function [1]. 
Disease-associated malnutrition is a common problem 
among patients with cancer, affecting more than 50% of 
patients with certain cancers (e.g., pancreas, esophageal, 
gastrointestinal, and head and neck cancers). Acute and 
chronic inflammation play a major role in the pathogenesis 
of cancer-related malnutrition [2]. Altered nutritional 
status may be due to increased nutrient requirements of 
the tumor, changes in host metabolism induced by tumor 
or due to side effects of aggressive anti-cancer therapies 
[3]. PCM in cancer patients is caused by several factors 
including loss of appetite, altered taste, and smell, physical 
inability to ingest food and metabolic alterations including 
insulin resistance, glucose intolerance, energy imbalance 
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and increased lipolysis and proteolysis. These factors are 
influenced by the type of cancer, local tumor effects, the 
anticancer therapy being employed, and psychosocial 
response to therapy [4, 5]. 
Weight loss in cancer patients is often characterized 
by loss of muscle mass and adipose tissue which is 
different from starvation induced weight loss [6]. If left 
untreated, it often progresses to severe wasting associated 
with cancer anorexia-cachexia syndrome (CACS). CACS, 
a condition of advanced PCM, is a major paraneoplastic 
syndrome characterized by metabolic abnormalities and 
loss of skeletal muscle with or without loss of adipose 
tissues. Anorexia, clinically defined as a loss of appetite 
or desire to eat is present in 15-20% of cancer patients at 
diagnosis, and is a common side effect in individuals with 
metastatic disease [7]. Anorexia is a major component of 
cachexia. 
Cancer cachexia is clinically categorized by severe 
loss of skeletal muscle and overall - body mass due to 
metabolic alterations and advanced malnutrition. Cachexia 
is defined as weight loss of more than 5% of body weight 
in 12 months or less in the presence of chronic illness; 
cachexia is also defined as a body mass index (BMI) less 
than 20 kg/m2 accompanied by three of following criteria: 
decreased muscle strength, fatigue, anorexia, low fat-free 
mass index, increased levels of C-reactive protein or IL-6 
and low serum albumin [8]. The European Society for 
Clinical Nutrition and Metabolism (ESPEN) identifies pre-
cachexia in cancer patients as unintentional weight loss 
of 5% within six months [7]. The underlying mechanisms 
of CACS are currently under extensive investigations and 
there are no clinically available biomarkers that would 
identify patients who are at a high risk of developing 
CACS.
Nutrient intake in cancer patients is also affected 
by abnormalities in gastrointestinal (GI) tract functions 
due to anticancer therapies. Commonly found symptoms 
involved in GI tract problems include nausea, vomiting, 
constipation and diarrhea. Tumor-associated and therapy-
associated pain and fatigue also adversely affect nutrient 
intake [9]. The extent and range of symptoms varies 
among patients, and there are no readily available 
clinical methods to identify patients who are more 
likely to develop serious complications. The American 
Society for Parenteral and Enteral Nutrition (ASPEN), 
the American Dietetic Association, and ESPEN suggest 
that physicians begin nutritional support in malnourished 
patients and in patients who may have difficulty eating 
[10-12]. The National Comprehensive Cancer Network 
(NCCN) suggests treating malnutrition in patients with 
life expectancies measured in months to years but not 
in patients with shorter life expectancies [12]. Here, we 
provide a comprehensive overview of factors affecting 
nutrient intake in cancer patients with a focus on 
nutritional support available for undernourished patients; 
we discuss promising biomarkers under investigation that 
may be used to identify patients who are likely to develop 
severe nutritional complications. 
TUMOR-INDUCED MOLECULAR 
CHANGES ASSOCIATED WITH CACS
The beginnings of malnutrition in cancer patients 
can be traced to molecular changes induced by tumor-
host interactions (Figure 1). Tumor cells have an elevated 
requirement for nutrients compared to normal tissues. 
Mobilization of metabolites by tumor, aimed at supporting 
its growth has a systemic effect on metabolism at the 
whole organism level which leads to the onset of CACS 
[13]. CACS occurs as a result of a number of factors 
including mechanical changes due to the tumor location, 
systemic inflammation resulting in altered catabolism, 
and anorexia and neuroendocrine changes occurring due 
to tumor presence. Skeletal muscle and fat loss in cancer 
patients caused by decreased protein synthesis, increased 
protein degradation, and increased lipolysis are not readily 
reversed through conventional nutritional support [14, 
15]. Increase in circulating inflammatory cytokines is 
implicated in regulating metabolic responses leading to 
both cachexia and associated anorexia [16].
Anorexia
Cancer anorexia involves alterations in signaling 
pathways modulating energy intake mediated by 
hormones (e.g., leptin), neuropeptides (e.g., Neuropeptide 
Y [NPY]), inflammatory cytokines (e.g., interleukin-1 
[IL-1], interleukin-6 [IL-6], tumor necrosis factor-alpha 
[TNF- α], and neurotransmitters (e.g., serotonin and 
dopamine) [17]. Peripheral signals including hormones 
and inflammatory cytokines being sent to the arcuate 
nucleus of hypothalamus cause variations in the balance 
of appetite stimulating neurotransmitters (e.g., NPY and 
Agouti Related Peptide [AGRP]) or appetite inhibiting 
neurotransmitters (Opiomelanocortin and Cocaine 
Amphetamine Related Factor [18]), which alter food 
intake [19, 20]. It has been reported that in patients with 
CACS, the melanocortin system is persistently activated 
[9]. Frequently used tools to diagnose anorexia in cancer 
patients such as the Functional Assessment of Anorexia/
Cachexia Therapy (FAACT) and the North Center Cancer 
Treatment Group (NCCTG) questionnaire are based on 
assessments of appetite and appetite related symptoms. 
However, anorexia is often under diagnosed, and the 
associated advancement of malnutrition effects become 
distinguishing features of cachexia [7]. 
Inflammatory responses
Pro-inflammatory cytokine activity increases during 
cancer progression, and systemic inflammation is the 
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hallmark of cancer cachexia indicated by production of 
acute-phase response (APR) proteins such as C-reactive 
protein and fibrinogen. Increased production of APRs 
could result in a higher requirement for amino acids 
compensated by increase in muscle catabolism [21]. 
Cachexia often appears with anorexia as a result of 
imbalances between pro-inflammatory (e.g., TNF-α, IL-1, 
IL-6, interferon-gamma [IFN-γ]) and anti-inflammatory 
cytokines (e.g., interleukin-4 [IL-4], interleukin-12 
[IL-12], interleukin-15 [IL-15]) [7]. Pro-inflammatory 
cytokines such as TNF-α, IL-1, IL-6, and IFN-γ are 
transported across the blood-brain barrier, and they 
interact with brain endothelial cells causing release of 
substances that affect appetite (Figure 1). These cytokines 
alter metabolic pathways in muscle, liver, and adipose 
tissue, which collectively contribute to cancer cachexia 
[22]. TNF-α has been implicated in wide range of 
cachexia- associated mechanisms including protein and 
lipid synthesis and degradation, gluconeogenesis and 
expression of Uncoupling proteins. It promotes skeletal 
muscle wasting by activating the NF-κB pathway [23]. 
Circulating levels of IL-6 has been shown to be elevated 
in cachectic cancer patients and it can activate signal 
transducer and activator of transcription3 (STAT3) which 
is known to be involved in muscle wasting [24]. Leukemia 
inhibitory factor, a member of IL-6 family, has also been 
implicated in pathogenesis of cachexia [25]. However, 
unlike anorexic patients, cachectic patients have both low 
leptin (inhibits appetite) levels and high ghrelin (stimulates 
appetite) levels [26, 27].
Metabolic alterations
Increased resting energy expenditure and 
a wide range of metabolic activity from hypo- to 
Table 1: Common anticancer therapy derived complications in advanced cancers
Anti-cancer therapy  Site/Agents CACS precursors Ref
Surgery
Oral cavity, larynx, pharynx Dysphagia, Xerostomia [48, 49]
Thoracic, esophagus Dysphagia, Dumping Syndrome,Pain during alimentation, Weight Loss. [52]
Stomach Dumping Syndrome, Malabsorption (fat, iron, calcium, vitamin B12) ,Weight Loss [9, 54, 56]




Colon Water and electrolyte loss [52]
Pancreas Malabsorption, Nausea, Vomiting [57-59]
Liver Transitory hypo-albuminemia [52]
Chemotherapy
Alkylating Agents Nausea, Vomiting, Mucositis, Stomatitis, Esophagitis, Diarrhea, Malabsorption [60]
Antimetabolites Nausea, Vomiting, DiarrheaLoss of appetite, Constipation. [203, 204]
Topoisomerase inhibitors Diarrhea [9]
Corticosteroids Electrolyte Abnormalities, Hyperglycemia, Pancreatitis [205]
Radiotherapy
Radiotherapy
Total Body Nausea, Vomiting [9]
Head and Neck
Mucositis, Odynofagia, Dysguesia,




Esophagus Reflux, Dysphagia, Odynophagia, Fibrosis, Stenosis Fistula [88]
Lung Odynophagia, Nausea, Fibrosis [9, 88]
Abdomen and pelvis
Vomiting, Diarrhea, Acute Enteritis, Colitis, Inflammation 







Toxicity to normal tissues (trastuzumab) ,induction of 
severe autoimmunity (ipilimumab) 
[91]
Cytokines Nausea, Vomiting [92]
Immune System Checkpoint Targets Diarrhea [91]
Hematopoietic and 




Graft –versus –Host Disease
Mucositis, Eythema, Pain, Xerostomia, Ulcers, Mucocele
Restriction of mouth opening from sclerosis [93]
GI Tract
(GVHD complications) Nausea, Vomiting, Weight loss [93]
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hypermetabolism have been reported in cancer patients 
[28]. Hypermetabolism in malnourished patients 
contributes to a negative energy balance, which manifests 
in weight loss. Resting energy expenditure has been shown 
to vary by tumor type. Gastric and colorectal cancer 
patients tend to have normal resting energy expenditure, 
while pancreatic and lung cancer patients have higher 
resting energy expenditure [29]. The increase in resting 
energy expenditure experienced by lung cancer patients is 
generally the result of a systemic inflammatory response 
[30].
Increased glucose oxidation, protein turn over and 
lipolysis are widely observed metabolic disturbances 
in cancer patients. Altered carbohydrate metabolism in 
cachexia is characterized by insulin resistance, glucose 
intolerance, and gluconeogenesis from amino acids and 
lactate [31]. Increased energy consumption in cancer 
patients due to alterations in glucose metabolism has been 
reported. Tumor suppressors, p53 and Vhl, which increase 
dependence on glucose, are often lost in cancer patients 
[32, 33]. In addition, the hypoxic environment of the 
tumor and hypoxia-inducible factor I induce the formation 
of lactate [34]. Excess lactate can enter the Cori cycle in 
the liver and be converted back to glucose, increasing net 
ATP consumption (Figure 1). This has been documented 
in weight loss occurring cancer patients [35]. It has also 
been reported that gluconeogenesis and glycogenolysis 
are increased in cancer patients who experience weight 
loss [36]. The change in glucose level in cancer cells has 
been estimated to account for 40% of the increased energy 
expenditure in metastatic cancer [31]. 
During cachexia, the balance between muscle 
protein catabolism and anabolism is disrupted. Decrease 
in levels of anabolic factors and increase in catabolic 
factors have been observed in patients and cachectic 
mouse models. Circulating levels of insulin-like growth 
factor-1(IGF-1), an anabolic factor is decreased in 
cachectic patients [37]. Expression and production of a 
negative regulator of IGF-1 and insulin signaling, Impl2, 
has been observed in different tumor types. This can lead 
to insulin resistance and tissue wasting [38]. Factors that 
are upregulated during muscle atrophy include cytokines, 
activin A, myostatin and TNF-α receptor adapter protein6 
(TRAF6) [39-41]. Different proteolytic pathways in the 
muscle including the ubiquitin-proteasome and autophagy 
dependent pathways are found to be upregulated in 
cachectic patients. Mitochondrial metabolism in cachectic 
muscles is also affected. Uncoupling proteins that reduce 
proton gradient, produce reactive oxygen species and 
promote thermogenesis are overexpressed in muscle tissue 
[42]. 
Tumors can also cause increased mobilization 
and oxidation of lipids that result in increased energy 
expenditure (Figure 1). Lipid mobilizing factor, produced 
Figure 1: Tumor induced changes in different organs leading to the development of CACS. CACS is a multi-organ 
syndrome promoted by different factors secreted by tumor like cytokines and Lipid Mobilizing Factor (LMF). These factors induce changes 
in metabolic pathways and variations in appetite ultimately leading to loss of skeletal muscle mass.
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by cachexia-inducing tumors, causes the release of 
free fatty acids and glycerol from adipose tissue [43]. 
Lipolysis is also induced by IL-1, IL-6, TNF-α and TNF-γ 
[43, 44]. Cancer patients exhibit increased expression of 
mitochondrial uncoupling proteins in brown adipose tissue. 
Increased expression of uncoupling protein-1 in brown 
fat results in the loss of proton gradient, which causes 
uncoupling of ATP synthesis and oxygen consumption 
leading to increased metabolism and generation of heat. 
High uncoupling protein-3 mRNA levels are observed 
in gastrointestinal patients experiencing weight loss 
[45]. Studies in a knockout mouse model have indicated 
that activin signaling may play a role in controlling 
mitochondrial uncoupling and energy expenditure [46]. 
NUTRITIONAL COMPLICATIONS 
ARISING FROM ANTI-CANCER 
THERAPIES
Patients suffering from cancer and/or receiving 
anticancer therapy experience a variety of physiological 
manifestations that negatively affect appetite and dietary 
intake (Table 1). These side effects can result in reduced 
food intake, improper digestion, and nutrient absorption 
leading to the development of anorexia. 
Surgery
Efforts to correct nutritional deficiencies should be 
made prior to surgery to improve the rate of treatment 
success, however this may be difficult to accomplish 
if surgery is adjuvant to chemoradiation treatment. 
Nutritional complications of surgery vary by cancer site. 
Oral and esophageal resections often cause reduced food 
consumption and increased nutritional requirements that 
persist long after surgery [47]. Mastication complications 
may continue for a year in as many as 50% of post-
surgery patients [48, 49]. Surgical intervention on the 
tongue, salivary glands, or olfactory nerves can cause loss 
of taste and smell, which can lead to reduced food intake 
and negative nutritional effects [47]. As many as 50% of 
pharyngo-laryngectomy and 42% of laryngectomy patients 
experience dysphagia and chronic xerostomia for three to 
five years post-surgery [50, 51]. As many as 50-60% of 
patients undergoing esophagectomy experience loss of 
hunger, which is accompanied by reflux; 75% suffer from 
postprandial dumping syndrome, and 80-90% experience 
early satiety. Associated symptoms include dysphagia, 
weight loss, increased stool frequency, and dumping 
syndrome which consists of abdominal cramps, nausea, 
dizziness, diarrhea, and diaphoresis (Table 1) [52]. 
Surgeries of the gastrointestinal tract result in 
alterations to digestion and absorption of nutrients. Akin 
to head and neck surgeries, dysgeusia and dysosmia have 
been reported to occur in half of all patients undergoing 
upper gastrointestinal surgery; symptoms generally resolve 
within a 6- to 12-month timeframe [53]. However, 80% of 
cancer patients undergoing gastrectomy are malnourished 
due to maldigestion, malabsorption, shortened intestinal 
transit time, and bacterial overgrowth [54, 55]. Factors 
that influence maldigestion and malabsorption include 
lack of gastric hormones (partly caused by vagotomy) 
and the body’s inability to stimulate biliary and pancreatic 
secretions [56].
Malnutrition subsequent to pancreatico-
duodenectomy is often an outcome of disease progression, 
extent of parenchymal resection, and functional status of 
the remaining pancreas [57, 58]. Within two years post-
surgery, more than 50% of patients develop pancreatic 
exocrine insufficiency. The loss of enzymatic activity in 
the intestinal lumen, particularly loss of lipase activity, 
results in malabsorption of fat, protein, starch, and fat-
soluble vitamins, such as A, D, E, and K [59]. 
Chemotherapy
Toxicity of chemotherapy induces a host of 
complications in cancer patients including nausea, 
vomiting, anorexia, taste and smell changes, early 
satiety, mucositis, esophagitis, diarrhea, xerostomia, 
and constipation (Table 1). These symptoms occur as a 
function of the length and number of treatments. One 
of the most notable features of chemotherapy is nausea, 
which occurs in 84% of patients. Nausea occurring within 
24 hrs of treatment is mediated by activation of serotonin 
type 3 receptors, while delayed symptoms involve several 
factors including adrenal hormones, substance P, and 
gastrointestinal motility disruption [9].
In addition to decreased nutrient intake, metabolic 
abnormalities such as hyperglycemia and hypercalcemia 
occur post chemotherapy [53]. Alkylating agents such as 
cyclophosphamide, ifosfamide, or methotrexate can cause 
malabsorption by inducing direct mucosal and metabolic 
alterations [60]. Due to alterations from mucositis, 
erosive lesions may appear in the gastrointestinal 
tract [53]. Antineoplastic agents such as fluorouracil, 
doxorubicin, methotrexate, and cisplatin can induce severe 
gastrointestinal complications [61] . Biological therapies 
with interferons or with monoclonal antibodies, such as 
bevacizumab or cetuximab, can cause low to moderate 
nausea and/or vomiting. Tyrosine kinase inhibitors, such 
as lapatinib cause diarrhea [9]. 
Taste changes are common, and occur in 45-84% of 
cancer patients receiving chemotherapy [62-66]; changes 
in the ability to smell occur in 5% to 60% of patients [67-
69]. Patients with head and neck tumors have an especially 
high prevalence of chemosensory disorders [70, 71] due 
to the location of their cancer and the long-term effects 
of cancer therapies [72]. Chemosensory dysfunctions 
affect food intake and appetite [73-75] leading to the 
development of food aversions and weight loss [76, 77]. 
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Taste changes have been assessed by electrogustometry 
[78-80], which involves the application of an electric 
current to the tongue. Berteretche et al found an increase 
in electrical taste detection thresholds in chemotherapy 
patients compared to healthy controls [62]. Ovesen et al. 
observed decreased electrical taste detection thresholds 
in patients with different solid tumors undergoing 
chemotherapy compared to control patients with non-
cancerous disease [81]. In lung cancer patients and 
treatment responders, multiple studies have reported 
a decrease in electrical taste detection thresholds post 
chemotherapy compared to pre-chemotherapy [79, 81]. 
Chemotherapy patients showed increased chemical 
taste thresholds assessed by application of dilutions 
of basic taste substances [67, 79, 80, 82, 83] or with 
impregnated filter paper Taste Strips [84]. Higher 
thresholds were found for bitter [85, 86], sweet [86, 87], 
sour [84, 86], and salty tastes [86]. However, in other 
studies changes or variations in sensitivity to different 
concentrations were not observed [82, 83]. Because these 
studies involved small sample sizes, these contradictory 
findings might be artefactual. 
Few studies have prospectively investigated 
smell alterations in chemotherapy patients. However, 
multiple studies have reported that smell thresholds were 
unchanged during chemotherapy [69, 81]. Yakirevitch 
et al. observed that smell thresholds were increased 
after the end of treatment, although there was no change 
during chemotherapy [69]. Steinbach et al. also reported 
a decrease in olfactory function during chemotherapy, 
and found that compared to smell thresholds, smell 
discrimination and identification were largely unaffected 
[84]. 
Radiotherapy
The side effects of radiation therapy depend on the 
area irradiated, total dose, fractionation, duration, and 
volume irradiated. Side effects last several weeks; patients 
only begin the process of healing after the first 2-3 weeks 
out from treatment due to the continued radiation effects. 
Because of this,, 90% of patients that undergo irradiation 
for head and neck, thoracic, abdominal, and pelvic tumors 
become malnourished and experience weight loss (Table 
1) [9]. Radiotherapy of the head, neck, and thorax can 
cause xerostomia, mucositis, hypophagia, and pain. 
Radiation treatment of the oral cavity causes nausea, 
vomiting, dysphagia, odynophagia, sore throat, anorexia, 
esophagitis, mucositis, xerostomia, tissue ulceration, and 
taste alterations [9]. Oral cavity irradiation can have direct 
toxic effects on taste buds through effects on innervating 
nerve fibers, and can affect secretary cell functions in 
the mouth, reducing output and altering viscosity of 
saliva [53]. Acute esophagitis is a common side effect 
of radiotherapies for intra-thoracic neoplasms following 
chemotherapy or of radiotherapy exceeding 50 Gy, which 
is the case for 30% of cancer patients [88]. 
Abdominal irradiation often causes malabsorption 
because of direct toxic effects on microvilli of the 
gastrointestinal mucosa. Nausea or emesis occurring 
around three days post-irradiation is reported in 
approximately 50% of patients receiving upper abdominal 
radiation [9, 89]. Radiation induced emesis occurs in more 
than 90% of patients receiving total body irradiation [9].
Chronic radiation enteropathy is another 
complication that has a strong negative effect on the 
nutritional status of cancer patients due to the formation of 
multiple severe gastrointestinal strictures and fistulas [47]. 
In the chronic phase, when a stenosis occurs following 
esophagitis, the most common intervention is the initiation 
of enteral nutrition; otherwise, esophageal dilation and 
stent placement are necessary [9]. Symptoms are usually 
most severe in the week following radiation, but generally 
plateau and may wither thereafter [90]. The pain caused by 
these side effects may be severe enough to limit adequate 
hydration and nutrition [9]. 
Immunotherapy
Depending on the specific therapy used, 
immunotherapy can cause gradual or drastic weight 
loss. Monoclonal antibodies, which are used to block 
cancer-cell receptors for growth-stimulating factors, 
may cause a cascade of symptoms due to their inherent 
toxicity and possible autoimmune manifestations [91]. 
Cytokine therapy involves the therapeutic introduction of 
cytokines to induce the immune response to disrupt tumor 
growth. Treatments with cytokines such as interleukin 
2 or granulocyte-macrophage colony stimulating factor 
produce side effects including weight loss, fever, nausea, 
vomiting, and diarrhea (Table 1) [92].
Hematopoietic and peripheral blood stem cell 
transplantation(HSCT)
Patients receiving allogeneic donor stem cells often 
develop mucositis depending on the level of cytotoxicity 
of the immunosuppressive drug regimen, and may have 
difficulty meeting caloric needs [93]. Often the nutritional 
deficiencies result from acute graft versus host disease 
(GVHD), especially of the alimentary tract, resulting in 
taste changes, oral dryness, thick saliva, mouth and throat 
sores, nausea and vomiting, diarrhea, constipation, lack of 
appetite/weight loss, and weight gain [93]. 
NUTRITIONAL SCREENING IN CANCER 
PATIENTS
Patients at high risk of developing PCM can be 
identified using simple, non-invasive tools, which are 
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sufficiently sensitive to predict nutritional deterioration 
under current and likely future circumstances associated 
with disease processes. Thus, identified high-risk patients 
should be seen by an expert for detailed assessment of 
metabolism, body composition, and other variables to 
determine an appropriate nutritional therapy regimen. 
Nutritional screening should ideally be done before the 
start of anti-cancer therapy so that the nutritionist and 
dietician can give informed dietary recommendations 
according to scheduled treatment. Three commonly 
used nutritional screening tools used in assessment of 
oncology patients are Nutritional Risk Screening (NRS-
2002), Malnutrition Screening Tool (MST), and the more 
detailed Patient-Generated Subjective Global Assessment 
(PG-SGA) [94].
NRS-2002 generates a nutritional score based on 
change in dietary intake, recent weight loss, BMI changes, 
and a subjective assessment of disease severity[95]. NRS-
2002 is widely used in evaluating hospitalized patients, 
and is a good predictor of post-operative complications 
in cancer patients [96, 97]. MST is a three question test to 
assess loss of appetite and recent weight loss in medical, 
surgical, and oncology patients [94]. MST has been 
accepted as a predictable test for identifying high-risk 
oncology outpatients, especially those who are undergoing 
radiotherapy [98]. Subjective Global Assessment (SGA) is 
a widely used objective method based on medical history 
and patient physical examination [99]. PG-SGA has been 
specifically tailored for cancer patients incorporating an 
expanded questionnaire and a numerical scoring system 
[100, 101]. SGA is the most commonly used system for 
nutritional assessment, and is considered to be the gold 
standard for evaluating oncology patients. 
In patients with increased risk of malnutrition, a 
detailed evaluation accompanied with data collection 
is recommended. Information that need to be gathered 
include demographic and anthropometric data, details 
on the disease and its treatments and biochemical data 
which includes the plasma concentrations of positive and 
negative APR proteins [102]. Although bodyweight is 
the most important endpoint of any cachexia treatment, 
any tool used should include measurements for body 
composition, physical performance status such as Eastern 
Co-operative Oncology group (ECOG) score for cancer 
patients and quality of life. Clusters of multiple parameters 
are recommended for assessment to avoid interference 
from tumor derived factors[2].
MANAGEMENT FOR NUTRITION-
RELATED COMPLICATIONS
Adequate calorie and nutrient intake is imperative 
for the management of cancer-related symptoms and 
adverse effects of treatment. In general, the most highly 
recommended diet for cancer patients is a high calorie, 
high protein diet that includes a wide variety of fruits, 
vegetables, and proteins, and is low in saturated fats, but 
high in monounsaturated fats. Aggressive efforts should 
be made to ensure that patients continue to consume 
foods that are high in calories and protein to meet their 
nutritional needs throughout the course of their treatment 
(Figure 2).
Due to the complex nature of complications arising 
from cancer or anti-cancer therapies, a significant effort is 
necessary to identify drugs that can alleviate the symptoms 
and provide relief to patients. Although drugs are approved 
by the FDA for safety, clinical trials focused on assessing 
effectiveness for treating symptoms have been limited 
(small patient cohorts, lack of complete patient history). 
Despite these shortcomings, drugs have been identified 
that are effective for treating symptoms arising from 
cancer and anti-cancer therapies (Supplementary Table 1). 
Anorexia
Anorexia is one of the most common problems 
for cancer patients. To manage anorexia, cancer patients 
are advised to eat small high-protein and high-calorie 
meals every 1-2 hours instead of 3 larger meals, and 
take to liquid supplements (special drinks containing 
nutrients) [47]. Eating more dairy products also helps to 
ameliorate anorexia (Figure 2). Also, insure that patient is 
not suffering with constipation and if so discuss methods 
for relief as constipation can promote feelings of poor 
appetite/intake/early satiety and aggravate anorexia.
The most widely employed appetite stimulants 
used to treat anorexia are Megestrol acetate (Megace) 
and Medroxyprogesterone acetate (MPA), both of which 
are synthetic progestins, which stimulate appetite via 
Neuropeptide Y (NPY)-release in the hypothalamus 
[103] or by downregulating synthesis and release of 
proinflammatory cytokines [104]. Anorexia has been 
shown to be treatable with androgenic and anabolic 
steroids including nadrolone, decanoate, and oxandrolone 
[105-107].
Cachexia
The majority of cancer patients experience weight 
loss as their disease progresses. Nutritional management 
of cachexia in cancer patients involves intake of high-
protein and high-energy foods. Supplementation with 
eicosapentaenoic acid, antioxidants, and proteins may 
reverse severe weight loss in cancer patients with high 
inflammatory stress [108]. However care has to be taken 
to avoid interference of the supplements in inflammatory 
response induced by treatment aimed at destroying 
cancer cells. Hence antioxidant supplements are only 
prescribed in practice several months or years post 
treatment. A combination of ß-hydroxy-ß-methylbutyrate 
(HMB), arginine, and glutamine has demonstrated an 
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overall benefit including increased lean body mass, 
improved emotional profile, less weakness, and improved 
hematological parameters [109]. 
Although multifactorial, cachexia can be treated 
with corticosteroids such as dexamethasone, prednisolone, 
and methylprednisolone that enhance appetite and 
sensation of well-being [110]. Several neuropeptides 
regulate appetite, and are currently undergoing clinical 
trials to determine their efficacy in the treatment of cancer 
cachexia. Among these is ghrelin, a neuropeptide released 
from the stomach in response to fasting that stimulates 
food intake and improves total and lean body mass. 
Ghrelin has been suggested as a therapeutic approach for 
the treatment of cachexia [111]. Anamorelin, a ghrelin 
agonist has completed phase III trials in which it was 
shown to have a significant impact on reversal of skeletal 
muscle loss and a positive effect on appetite and weight 
gain [112]
Figure 2: Nutritional support strategies for common physiological complications arising from anti-cancer therapies.
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Dysphagia
Dysphagia associated with head, neck, and 
esophageal tumors can persist despite surgical excision 
of the tumor mass. Mechanical dysphagia can morph into 
neurogenic dysphagia due to ablations of muscular and 
nervous tissue, and presence of chemo and/or radiotherapy 
[113, 114]. Nutritional deficiencies caused by mechanical 
dysphagia can be avoided by early enteral nutrition [9]. 
Improving the texture of food presented in smoothie form 
using food thickeners, diluents, and lubricants is highly 
recommended. Fats consumed in smaller volumes can 
increase calorie intake [115]. 
Dumping syndrome 
Dumping syndrome usually follows gastrectomy 
and esophagectomy. Early dumping syndrome occurs 
immediately following meals rich in simple carbohydrates 
due to rapid abdominal distension with the release of 
vasoactive substances such as serotonin and bradykinin 
[9]. This can be avoided by small, frequent meals high 
in protein and complex carbohydrates, and allowing 
a 40 minute gap between food and drink ingestion 
(Figure 2). Complex carbohydrates rich in fiber delay 
glucose absorption and prolong bowel transit time. 
Supplementation with dietary fiber, including pectin 
and guar gum, has been shown to effectively treat 
hypoglycemia [116]. Late dumping syndrome occurs 2-3 
hours following a meal due to a postprandial hypoglycemia 
crisis that develops due to hyperinsulinemia induced by 
a rapid influx of glucose into the blood [116]. Avoiding 
sugar containing drinks and alcohol is also recommended 
to prevent late dumping [115]. 
Nausea and vomiting
Before and during chemotherapy/radiotherapy, 
patients may experience anticipatory nausea and vomiting. 
In addition, tastes, smells, visual cues, and thoughts might 
trigger the onset of emesis [117, 118]. In general, nausea 
can be avoided by eating dry, non-spicy foods after 
waking up and every few hours during the day. Foods that 
are overly sweet, greasy, fried, spicy, or have strong odors 
should be avoided. Nausea can also be avoided by sitting 
up or reclining with head raised for at least an hour after 
eating. Care should be taken to drink sufficient liquids 
to prevent dehydration. A bad taste in the mouth can be 
ameliorated by sucking on hard sweet candies or chewing 
peppermint chewing gum [119]. Avoid hot, stuffy rooms 
or strong cooking odors by using baking bags as well.
Metoclopramide, Haloperidol, Cyclizine, 
Domperidone, Ondansetron, Scopolamine, 
Prochlorperazine, Chlorpromazine, and Levomepromazine 
have been found to be effective in reducing the severity 
of nausea and vomiting arising from chemotherapy [120-
123]
Oral complications
Oxidative stress caused by chemotherapy and 
radiotherapy often leads to inflammation resulting in 
a host of ulcer-inducing alimentary tract inflammatory 
symptoms. Mucositis is often related to antimetabolites 
(e.g., 5-fluorouracil), antitumor antibiotics, taxanes, 
cisplatin, etoposide, cyclophosphamide, and irinotecan 
[124, 125]. Oral mucositis develops in a significant 
number of patients undergoing chemotherapy for 
different cancers and patients undergoing radiotherapy 
for head and neck cancers. Pain control, nutritional 
support, oral decontamination, management of bleeding 
and dry mouth and therapeutic interventions are used in 
the clinic to tackle the condition [126]. Cryotherapy is 
often performed in conjunction with chemotherapy. Oral 
rinsing with ice water or sucking on ice chips causes 
local vasoconstriction, which reduces the distribution of 
drug, reducing the severity of oral mucositis[127-129]. 
In combination with induced myelosuppression caused 
by antimetabolites, mucositis can result in viral and 
bacterial infections. Oral washes with baking soda or salt 
can be used to prevent infection and to provide soothing 
effects [129]. Frequent dental examinations decrease the 
possibility of infection, as well. 
Head and neck cancer patients suffering from 
xerostomia (dry mouth) have shown improvement when 
treated with Amifostine, Pilocarpine, and Cevimeline, 
which are cholinergic agonists that work by stimulating 
certain nerves to increase saliva production [130-
132]. In addition, head and neck cancer patients may 
suffer from mucositis for which analgesic therapy and 
antibiotics/antifungals are given in addition to drugs 
such as Palifermin [Keratinocyte growth factor (KGF) 
produced by recombinant DNA technology] to prevent 
infection[18]. Mouthwashes containing diphenhydramine, 
lidocaine, nystatin, and corticosteroids are also used in 
clinical practice [127, 129].
Diarrhea
Severe diarrhea is usually treated with a combination 
of clear liquid intake of at least 3 L per day, water soluble 
fiber supplements, and anti-diarrheal drugs[133]. It is 
helpful to eat small, frequent meals, while avoiding 
alcohol, caffeine, gas-forming food or drink, high fiber 
foods, high fat foods, and spicy foods. Lactose intolerant 
patients should avoid lactose-containing foods. Diarrhea 
resulting from anti-cancer therapies can be treated with 
Imodium, Cholestyramine, Diphenoxylate, and Octreotide 
acetate [120-123, 134]. These drugs can also be used in 
conjunction with anti-inflammatory drugs and antibiotics 
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to treat radiation enteritis [135]. Probiotic supplementation 
is a potential preventive method for diarrhea resulting 
from radiotherapy to the lower abdomen and pelvis. In a 
study of 490 patients receiving surgery for sigmoid, rectal, 
and cervical cancers, supplementation with VSL#3® 
(VSL Pharmaceuticals, Inc) before and during subsequent 
radiation led to a significant difference in the number 
of bowel movements and toxicity of diarrhea [133]. 
Supplementation with another potential preventative 
probiotic, Lactobacillus acidophilus, significantly reduced 
diarrhea in 1748 patients following radiation to the pelvis 
[136]. In addition, to reduce radiation-induced diarrhea, 
psyllium fiber supplementation is helpful [137, 138].
Dysgeusia and dysosmia
Dysgeusia is a distortion of the sense of taste and 
dysosmia is any alteration of the perception of smell. 
Dysgeusia is a condition in which a foul, salty, rancid, 
or metallic taste sensation persists in the mouth and also 
often associated with ageusia, which is the complete lack 
of taste, and hypogeusia, which is a decrease in taste 
sensitivity. Often, people who feel they have a problem 
with their sense of taste are experiencing a loss of smell 
instead of a loss of taste [139]. Zinc plays an important 
role in taste perception, and zinc deficiency is often 
responsible for taste perception abnormalities in otherwise 
healthy persons [140], in various diseases [86, 141], and 
in drug-induced taste disorders [142]. Beneficial effects 
of zinc sulfate [80, 143, 144] or polaprezinc (zinc-L-
carnosine) [145] on taste disturbances have been reported 
in patients with head and neck cancer or lung cancer 
(Figure 2). However, a phase III trial found no significant 
effect of zinc sulfate therapy on the median interval to 
taste alterations following radiotherapy, and no significant 
benefit of zinc therapy on taste or smell was found among 
cancer patients undergoing chemotherapy [146, 147]. 
Zinc supplementation should be used cautiously until 
further research confirms its efficacy, because long-term 
and excessive consumption of zinc may have a negative 
impact on the immune system in cancer patients [148]. 
Zinc supplementation should not go on beyond 3 months 
as iron and copper stores can be lowered.
Drugs such as bovine lactoferrin, which can 
treat taste alterations, are currently undergoing clinical 
study. Results of a randomized placebo-controlled 
pilot study to determine if administration of delta-9-
tetrahydrocannabinol (THC) improved taste and smell 
perception as well as appetite, caloric intake, and quality 
of life for cancer patients with chemosensory alterations 
showed that treatment with THC improved chemosensory 
perception as well as appetite in patients with advanced 
cancer [149]. THC increases appetite via endocannabinoid 
receptors (CB1r) [150]. CB1r are located in reward-
related areas of brain and in the olfactory epithelium and 
bulb [151, 152]. CB1r are involved in peripheral odor 
processing and potentially in taste function [151, 153]. 
A detailed list of drugs used for treating therapy-related 
symptoms is provided in Supplementary Table 1.
Metallic taste is frequently reported by cancer 
patients [154]. After at least two cycles of chemotherapy, 
78% (29/37) of patients with various cancer types 
described their perceived taste change as metallic [64]. 
Several strategies have been suggested for managing 
metallic taste. The most commonly mentioned strategy 
is the use plastic instead of metallic utensils [77, 155]. 
Patients receiving cyclophosphamide as part of their 
treatment reported a slight but lingering metallic taste; a 
few of these patients reported that using plastic utensils 
made food more palatable [156]. In patients with 
lymphoma, breast, lung, or ovarian cancer, consumption 
of cold foods was found to be more helpful for metallic 
taste than for other taste alterations [64]. In a study of 
ten colorectal cancer patients treated with oxaliplatin-
containing chemotherapy, one patient reduced the metallic 
taste through the use of very strong flavors, such as lots of 
salt [157]. 
A new approach was suggested in a pilot study using 
the fruit Synsepalum dulcificum, also known as “miracle 
fruit,” to improve food palatability for patients receiving 
chemotherapy [158]. “Miracle fruit” was developed as 
a sweetness enhancer. It contains the protein miraculin, 
which binds to sweet receptors on the tongue, having 
the effect of turning sour-tasting foods into sweet, and 
providing short-duration masking of certain unpleasant 
tastes, including metallic [159]. However larger studies are 
warranted on possible side effects of using miracle fruit 
since its antioxidant activity could interfere with the action 
of some chemotherapeutic drugs such as doxorubicin 
and platinum compounds. Also, stomach ache and sore 
throat have been reported with use. Lipid oxidation is 
thought to play a role in the development of metallic taste. 
Lipid oxidation may be reduced or prevented by use of 
antioxidants and chelating agents. A study of the effect 
of antioxidants (Vitamin C and E) and chelating agents 
(Ethylenediaminetetraacetic acid and lactoferrin) on the 
perceived intensity of metallic taste and lipid oxidation 
in healthy participants (22 participants, age 19-53 years) 
[160]. The antioxidants were not effective in removing 
the metallic taste, but the chelating agents were effective; 
lactoferrin completely eliminated the metallic taste in all 
participants.
Radiation enteritis
The use of radiation in the treatment of cancer comes 
with risks, one of which is radiation enteritis. Radiation 
enteritis is inflammation of the small and/or large intestine 
resulting from radiation treatments of the stomach, sexual 
organs, bladder or rectum. More than one fifth of patients 
receiving radiotherapy will develop radiation enteritis, 
with chronic enteritis developing between 18 months 
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Table 2: List of studies evaluating candidate biomarkers for CACS and therapy-associated complications
Physiological 
Conditions Biomarker Function Comparison/ Purpose Results Ref
CACS
IL-1β Pro-inflammatory cytokine
Plasma levels of pro-
inflammatory cytokines in 
advanced cancer patients
IL-1β levels strongly associated with 
subjective (weight loss, loss of appetite) 
and objective (albumin and CRP levels) 
measurements of cancer cachexia. 
[206]
IL-6 Pro-inflammatory cytokine
Identification of high risk factors 
contributing to increased serum 
IL-6 levels in chemo-naïve 
advanced pancreatic cancer 
patients.
High serum IL-6 related to anemia (P < 0.01), 
high CRP levels (P = 0.02), severe fatigue (P = 
0.02) and hepatic metastasis (P < 0.01).
[207]
Serum pro-inflammatory 
cytokine levels in 
gastroesophageal patients.
IL-6 and other pro-inflammatory markers are 
elevated in cachetic gastroesophageal patients 
compared to non-cachetic (6.582pg/ml vs 




Serum IL-8 levels were 
compared between healthy 
controls, non-cachetic gastric 
cancer (GC) patients and 
cachetic GC patients.
IL-8 levels were significicantly higher in 
cachetic patients compared to non-cachetic 
patients and healthy subjects (1.413 ± 
0.130 ng/mL vs 0.899 ± 0.076 ng/mL). 
[209]
Serum IL-8 levels in 
gastroesophageal patients.
 IL-8 is elevated in cachetic patients compared 
to non-cachetic and healthy controls. [208]
Ghrelin
Gastric hormone 
involved in energy 
balance and 
hunger.
Role of ghrelin in cachexia and 
its potential as a diagnostic tool 
in NSCLC patients.
Serum ghrelin levels were higher in patients 
experiencing weightloss compared to healthy 
individuals (0.5 ± 0.4 ng/ml vs. 0.4 ± 0.3ng/
ml) and patients without weight loss. (0.56 ± 




involved in energy 
homeostasis
Predict potential of using leptin 
as a diagnostic and prognostic 
biomarker for cachexia in cancer 
patients.
Serum leptin was significantly lower in 
cachetic cancer patients with a diagnostic 
(sensitivity 79%, specificity 73%) and 
prognostic significance (HR 0.94; 95% CI 







Identification of blood based 
biomarkers of cachexia in 
advanced cancer patients.
 Pre-cachetic (~18±2pg/ml) and cachetic 
(~17±2pg/ml ) patients showed significantly 
elevated levels of angiotensin II in blood 








Measurement of plasma GDF-
15 levels in cancer patients 
compared to controls
Plasma GDF-15 levels were elveated in cancer 
patients experiencing weight loss compared to 
those who are not.(median levels of GDF-15- 
2.5ng/ml compared to 1.5ng/ml) 
[188]
Nausea and Vomiting Arginine Vasopressin202
Direct stimulation 
of the medullary 
vomiting center 
via vagal afferents
AVP levels in plasma of 
patients with vomiting after 
chemotherapy to those who 
don’t.
Increased levels of AVP in patients with 
vomiting symptoms(4 to 129 fold difference). [193]
Mucositis Citrulline
Inflammation 
caused by GI tract 
damage.
Usage of citrulline as a marker 
for GI mucositis in HSCT 
patients
Citrulline levels were <10µmol/L in patients 





Identification of biomarkers for 
chemotherapy-induced diarrhea 
in fecal samples of cancer 
patients 
Fecal calprotectin levels were increased in 
patients with diarrhea (6.82±1.20 ng/ml)








Transthyretin Thyroid hormone-binding protein
Identification of biomarkers for 
the condition in cervical cancer 
patients.
Patients with RIAIS showed significantly 
decreased levels of serum TTR compared to 








Identification of biomarkers for 
the condition in cervical cancer 
patients.
Patients with RIAIS showed significantly 
higher levels of serum TTR compared 









barrier function of 
intestinal mucosa
Identification of plasma 
biomarkers specifically for 
gastrointestinal GVHD.
REG3α levels showed 3 fold increase in 
patients with GI GVHD and serves as a 
prognostic indicator for non-relapse mortality.
[211]
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and 6 years following treatment [161-163]. It is often 
suggested that patients affected by radiation enteritis make 
changes in their diet to reduce aggravation to the digestive 
system. Among the recommendations are avoidance of 
dairy products (with exception of yogurt), whole wheat 
products, chocolate, and raw vegetables, and inclusion of 
protein-rich foods and fruits in the diet (Figure 2).
Nutrition support therapy
Moderately to severely malnourished cancer patients 
who are at risk of not receiving adequate nutrition for 7 
to 14 days following surgery would benefit from enteral 
nutrition (EN). Administration of an immune enhancing 
formula that includes supplemental arginine, ω-3 fatty 
acids, and nucleotides has been shown to decrease the 
incidence of surgical complications in these patients [164]. 
EN is also the preferred mode of nutritional support in 
post-operative malnourished patients as it is associated 
with reduced incidences of infectious complications and 
hyperglycemia [165]. EN delivered by feeding tube is also 
used in patients with head and neck cancer undergoing 
chemoradiotherapy. Depending on the tumor status and the 
patient’s nutritional status, administration of prophylactic 
or reactive enteral tube feedings is advisable to combat 
malnourishment [166]. 
Although oral and EN methods are preferred, 
parenteral nutrition (PN) is generally used when patients 
begin to experience severe side effects from anticancer 
therapies. PN is recommended when malnourished 
patients are unable to digest and absorb nutrients delivered 
enterally for more than 7 to 10 days [167]. Cachectic and 
hypophagic patients suffering from sub-acute intestinal 
obstruction due to peritoneal carcinomatosis may require 
long term PN [168]. PN is recommended in cases where 
severe mucositis or severe radiation enteritis is present, 
or when oral or enteral nutrition is not possible [169]. 
PN is not recommended for non-aphagic patients or for 
those with severe gastrointestinal obstructions, in which 
case PN is ineffective and possibly damaging but PN is 
typically recommended or even required for patients with 
gastrointestinal obstructions; in these cases, some terminal 
patients (3+ months expected lifespan) palliative PN 
should be considered, but is not a cancer-specific treatment 
and will not likely prolong the patient’s life [169]. 
PN will not increase survival in a patient who is 
undergoing chemotherapy and radiation therapy, and is 
only recommended for patients whose nutrient absorption 
is inadequate and EN is not possible [167]. In HSCT 
patients, PN is not routinely recommended but may be 
used to ensure nutrition in patients experiencing severe 
mucositis, ileus, and intractable vomiting [168]. Glutamine 
supplementation may be beneficial to these patients. PN 
should be discontinued when patients are able to attain 
50% of nutritional needs enterally [168]. If GVHD 
develops, patients should be put on PN, and are usually 
not taken off PN until bone marrow recovers [168]. In 
patients with incurable cancers, PN is recommended when 
life expectancy is greater than 2 to 3 months, EN is not 
plausible, PN will likely improve quality of life, and the 
patient requests this form of nutrition [168]. Both EN and 
PN involve risks, including psychological risks associated 
with stress and discomfort from feeding tube insertion. 
Common complications also include infections, metabolic 
issues such as hyperglycemia, electrolyte imbalances, 
diarrhea, and, in the terminally ill, fluid overload [169]. 
BIOMARKERS FOR NUTRITIONAL 
STATUS
Diagnosis and management of CACS is a challenge; 
identification of biomarkers to precisely diagnose CACS 
in early stages and to predict the progression and outcome 
would significantly impact treatment and survival of 
cancer patients. Here we list a few promising candidate 
biomarkers with diagnostic and prognostic significance in 
CACS (Table 2).
Ghrelin
Ghrelin is a circulating, gut-derived hormone that 
crosses the blood brain barrier, acts through growth 
hormone secretagogue receptor in several parts of the 
brain to stimulate appetite and increase food intake [170]. 
Given the significance of ghrelin in increasing food intake, 
multiple studies have looked at plasma or serum ghrelin 
levels in cancer patients. Ghrelin levels were elevated 
in 140 cachectic adults with different cancers compared 
to healthy controls [171]. Individual studies have also 
reported elevated ghrelin levels in cachectic patients 
with lung or colon cancer [27, 172, 173]. Biologically 
active octanoylated ghrelin and active to total ghrelin 
levels have also been found to be increased in cancer 
patients compared to non-cancer controls [174]. It has 
been suggested that increased ghrelin levels might be a 
compensatory response to weight loss. Lower ghrelin 
levels in cancer patients have also been linked to increased 
survival [171]. Detailed studies on regulatory mechanisms 
of production and secretion of total and active ghrelin 
levels in cancer patients at risk of developing cachexia are 
needed to evaluate the potential of ghrelin as a biomarker 
for cachexia. 
Leptin
Leptin is produced predominantly in adipose 
tissues, and is a pleiotropic cytokine involved in the 
regulation of energy homeostasis, metabolism, and 
immune function. Leptin receptor is expressed in 
several cancers, and leptin signaling has been proposed 
to be involved in carcinogenesis [175]. Plasma leptin 
Oncotarget24021www.impactjournals.com/oncotarget
concentration is dependent on the amount of fat tissue. 
Lung and gastrointestinal cancer cachectic patients show 
lower serum leptin levels, presumably due to decreased 
fat. However, leptin levels have been found to be elevated 
in breast and gynecological cancer patients due to factors 
other than cachexia, limiting the potential of leptin as a 
universal biomarker for identifying cachectic patients 
[43]. However, additional studies on the role of leptin in 
cachexia and use of leptin as a biomarker are warranted. 
Angiotensin II
Angiotensin II, the main component of the renin-
angiotensin system (RAS), increases protein degradation 
and apoptosis in skeletal muscle [176]. Angiotensin 
II inhibits the IGF-1 signaling pathway, which results 
in decreased protein synthesis. Increased angiotensin 
levels also cause elevated levels of TNF-α, IL-6, and 
myostatin, which results in increased protein degradation 
and attenuated protein synthesis. In addition, angiotensin 
II regulates anorexic/orexic associated neuropeptides to 
regulate appetite and food intake [177, 178]. Angiotensin 
II mRNA in blood and plasma levels of angiotensin II 
were found to be elevated in patients with different cancer 
types prior to anti-cancer therapy. Angiotensin II was 
found to be elevated in both pre-cachectic and cachectic 
cancer patients compared to patients without cachexia, 
suggesting that angiotensin II has potential as a biomarker 
for early detection of patients at increased risk [179]. 
Angiotensin converting enzyme inhibitors have been used 
to inhibit muscle wasting and improve weight loss, which 
further indicates the possible significance of angiotensin in 
management of cachexia [180]. 
Cytokines
Systemic inflammation is closely associated with 
development of CACS, and pro-inflammatory cytokines 
have been explored as potential biomarkers for cachexia 
(Table 2). Plasma levels of several pro-inflammatory 
cytokines including TNFα, IL-6, IL-1 and IFN-γ in 
circulation have been assessed as markers of cachexia 
[181-184]. Although levels of these cytokines were found 
to be elevated in multiple studies, the results were not 
consistent [185, 186]. Variations in assay sensitivities, 
short half-life of cytokines, and presence of natural 
cytokine inhibitors may be associated with differences in 
detected levels of cytokines [183]. The TGFβ signaling 
pathway has been implicated in development of cachexia, 
and its superfamily members including TGFβ-1 and 
Growth Differentiation Factor (GDF-15) have been found 
to be elevated in plasma of pre-cachectic and cachectic 
cancer patients experiencing weight loss [179, 187, 188].
MicroRNAs (miRNAs)
Recently, several miRNAs, short non-coding 
RNAs that play a significant regulatory role in several 
biological processes, have been found to play important 
roles in muscle wasting processes. Lung and pancreatic 
cancer-derived microvesicles expressing miR-21 were 
shown to activate TLR7 receptor and to induce apoptosis 
of skeletal muscle cells [189]. Global miRNA profiling 
in adipose tissues of gastrointestinal cancer patients with 
or without cachexia indicated that miR-483-5p/-23a/-
744/-99b were downregulated and that miR-378 was up 
regulated in cachexia. Upregulation of miR378 correlated 
with catecholamine-stimulated lipolysis in adipocytes and 
with expression of key lipolytic regulators [190]. These 
findings indicate a key regulatory role for miRNAs in 
cancer cachexia, and suggest that, with further analysis, 
miRNAs may provide useful diagnostic and prognostic 
markers.
BIOMARKERS FOR ANTI-CANCER 
THERAPY-RELATED SYMPTOMS
Identification of biomarkers that predict the 
likelihood of occurrence of particular physiological 
complications following cancer therapy is difficult, in 
part, because of the complexity of generating an accessible 
biomarker that accurately predicts outcomes under highly 
variable circumstances such as age, nutritional and health 
status, medication, metabolic activity, and therapeutic 
modality [191]. These issues can be complicated further 
by overlapping symptoms that may be regulated by similar 
physiological underpinnings [192]. Although difficult to 
identify, genetic anomalies that predispose to particular 
reactions to anticancer therapies and physiological 
changes associated with complications can be used as 
biomarkers (Table 2). 
Nausea and vomiting
The most common symptoms following anti-cancer 
therapy are nausea and vomiting, which have been found 
to correlate with an increase in the hormone arginine 
vasopressin [193, 194]. Vasopressin induces vomiting 
by activation of chemoreceptor trigger zones in the area 
postrema of the brain, which induces afferent pathway 
activation of the medullary vomiting center [193]. No 
other markers predictive for vomiting or nausea are 
known.
Mucositis
There is a need for readily accessible mucositis 
biomarkers. Current methods for symptom determination 
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are invasive and harmful to patients undergoing concurrent 
anticancer treatments. Several diagnostic biomarkers for 
determining mucositis in chemotherapy patients have 
been generated including 13CO2, Lactulose/Mannitol, 
and citrulline; the latter has been found to be an accurate 
indicator of mucositis in HSCT patients [195, 196]. 
These tests assess components of mucositis-activating 
mechanisms that encourage tissue turnover in damaged 
gastrointestinal tracts. In chemotherapy patients, mucositis 
usually occurs in conjunction with diarrhea, and can be 
indicated by increases in the enzyme MMP-3, by changes 
in bacterial flora, such as increases in Bacteroides spp., 
and by inflammation in the gut mediated by an increase in 
fecal calprotectin [197]. A further complication that may 
occur during GI turnover is malabsorption; however, there 
are no specific biomarkers to indicate malabsorption in 
cancer patients. Stool weight can be used to indicate lack 
of absorption [198]. 
Radiotherapy-related complications
Parotid gland [(18)F] fluorodeoxyglucose-labeled 
positron emission tomography-computed tomography 
(FDG-PET-CT) uptake has been found to be a possible 
biomarker for post-radiotherapy xerostomia [199]. In 
cervical cancer patients, radiotherapy is commonly 
performed in the pelvis, often resulting in mucosal 
dysfunction and numerous acute intestinal symptoms. 
Decreased levels of osteopontin (OPN) [200], a cytokine 
regulating mucosal protective functions through 
transduction pathways, and Transthyretin (TTR) [200], a 
transporter of thyroxine through the blood/brain barrier, 
have been associated with an increased chance of intestinal 
complications. 
FUTURE DIRECTIONS
Cancer patients suffer from cancer-induced and 
therapy- induced nutritional deficiencies (mainly protein 
and caloric). In patients with advanced cancers frequently, 
PCM advances to a serious and challenging problem, 
which is often not solved by increasing nutrient intake 
because it involves loss of lean body mass induced by 
metabolic alterations caused by the presence of the tumor. 
In patients with nutritional deficits at the time of diagnosis, 
treatments will likely aggravate side effects leading to 
suspension or decrease in dosage of therapy. To practice 
personalized cancer care, the clinic needs to monitor 
nutritional status of cancer patients right from diagnosis 
and throughout the treatment period. Currently, nutritional 
interventions are shown to have some beneficial effects 
on quality of life but there is little effect on mortality 
[201] and this minimal effect is likely caused by lack of 
early nutritional interventions. Research leading to more 
complete understanding of the relationship between 
complications of cancer treatment and progression toward 
malnutrition and acute nutritional deficits will allow for 
efficient measures to prevent the transition to cancer 
cachexia. 
Nutritional supplementation offered in conjunction 
with patient selection at early stage of anti-cancer therapies 
can help patients withstand the toxic effects of therapy 
[202]. At onset and throughout the course of illness, 
patients should receive ongoing nutritional counseling. 
For selected patients, personalized dietary counseling with 
their family is important, and has been shown to improve 
the patient’s nutritional status, decrease morbidity, 
and improve quality of life. Clinicians and healthcare 
providers should be equipped to educate the patient and 
family members on potential effects of a prescribed 
treatment regimen on nutrient intake, and should make 
dietary recommendations. Follow-up visits should include 
assessment of symptom control, weight, appetite, and 
function as part of continued medical surveillance and 
monitoring of health status. This level of care requires an 
interdisciplinary approach involving physicians, nurses, 
nutritionists, dietitians, and psychologists. 
Research aimed at preventing and treating 
malnutrition must consider the multifactorial nature of 
the condition, beginning with establishment of a uniform 
definition of cancer-related malnourishment that should 
be followed as an eligibility criterion. In conjunction 
with nutritional therapy, a focus should be placed on 
management of symptoms resulting from toxicities 
associated with therapy. If therapy- associated nutritional 
complications get worsened prospects of postponing 
treatment until patient gets sufficient nourishment 
should be considered. Targeting specific symptoms with 
preventative measures, appropriate nutritional support, 
and drug administration will be beneficial to patient 
recovery. Considering the important role that changes in 
taste and smell exert on food intake and appetite, and in 
health and health-related quality of life of cancer patients, 
an objective assessment of qualitative taste and smell 
changes and adequate interventions should be applied. As 
symptoms of taste and smell disorders vary widely from 
patient to patient, specific interventions that combine 
pharmacologic and non-pharmacologic treatments into 
daily routines should be employed and customized for the 
individual patient. 
Future directions in the field of cancer cachexia may 
also come from aggressive research efforts by scientists 
towards discovery and validation of “biomarkers” for early 
detection and prevention of cancer-induced weight loss. 
Research is also needed in the area of cancer-associated 
anorexia; reduced food intake is common among cancer 
patients, and effective therapies to improve appetite 
and daily caloric intake are lacking. Results from the 
study of candidate biomarkers that may predict possible 
physiological complications following anti-cancer therapy 
promise to facilitate effective management of treatment 
and to prevent progression toward cachexia.
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